Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival
Justin D. Kaner(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Idongessit Udoyen(Cornell University), Spencer Krichevsky(Cornell University), Nuria Mencia-Trinchant(NewYork–Presbyterian Hospital), Mónica L. Guzmán(NewYork–Presbyterian Hospital), Pinkal Desai(NewYork–Presbyterian Hospital), Ariel Schaap(Cornell University), Sangmin Lee(Korea Advanced Institute of Science and Technology), Duane C. Hassane(AstraZeneca (Singapore)), Michael Samuel(NewYork–Presbyterian Hospital), Gail J. Roboz(Cornell University)
Cited by 8
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k